Magnetic Group Signaling (MGS®) Technology

Magnetic Group Signaling (MGS®) standardizes NMR systems and sample processing to ensure reproducible results on different NMR instruments.

Learn more

numares Initiates Worldwide Commercial Launch of insightLPTM-S50 to Provide New Insights in Lipoprotein Research New test of lipoFIT® series test analyzes lipoprotein composition

Regensburg, Germany, 07 February 2017 – Fast-growing commercial-stage diagnostics company numares AG today announced the worldwide launch of its new, software-based test insightLPTM-S50, part of the Company’s lipoFIT® series for lipoprotein profiling. insightLP-S50 enables research groups worldwide to analyze lipoprotein composition in detail, thus creating new possibilities in lipid analytics. The test can help clarify how the lipoprotein composition affects the risk of diabetes or cardiovascular disease and determine the effects of individual nutritional habits on lipoprotein composition.

numares is an established developer and supplier of innovative high-throughput testing methods for medical diagnostics and biomedical research with expertise in the nuclear magnetic resonance (NMR) spectroscopic analysis of lipoproteins. Lipoproteins transport cholesterol and lipids throughout the body and have been involved in the development of arteriosclerosis and other cardiovascular diseases. Although it is assumed that the composition of individual lipoproteins may play a decisive role, this cannot be detected using the routine diagnostics available until now.

The insightLP-S50 test analyzes lipoprotein particles in detail and determines their respective quantity of the key compounds triglycerides, cholesterol and phospholipids. The insightLPTM-S50 measures a total of 41 parameters. ”By using our new test of the lipoFIT series, research can gain further important insights into the role of certain lipoprotein particles, particularly in the development of atherosclerosis“, says Dr. Titus Kaletta, member of the executive board of numares AG and chief operating officer responsible for the commercialization of the lipoFIT series. “The insightLP-S50 test allows researchers to look into lipoprotein particles and investigate whether and to what extent their structure correlates with an increased risk of a disease.”

The test principle of  insightLPTM-S50 is based on the evaluation of standardized NMR spectra that derive from serum samples when using numares’ software-based AXINON® system. The AXINON® system allows two already established in vitro diagnostic (IVD) tests to be used for the advanced analysis of lipoproteins. In 2015, numares launched two lipid tests, lipoFIT®-S100 and lipoFIT®-S100-400, which measure lipoprotein particle concentration, size and cholesterol for the assessment of cardiovascular risk. Since then, more than 1 million tests have been performed in the U.S. using numares’ technology. In Europe, this advanced lipid analysis is offered as IVD in cooperation with the German laboratory chain Limbach Group and under the brand name LipoComplete.

“The worldwide commercialization of insightLPTM-S50 is a further important step for boosting lipoprotein research and gaining new insights into diseases and processes in the human body,” explains Dr. Maximilian Zucker, member of the executive board of numares AG and head of R&D at numares. “All tests of the lipoFIT® series guarantee the highest data quality and comparability for researchers worldwide thanks to the in-process quality assurance of the AXINON® test system. This also allows for the unlimited reprocessing of data with further numares tests, focusing on new aspects each time. This is a great 

For further information please contact:

numares AG
Dipl.-Biol. Christiane Proll, MBA
Tel.:    +49 941 2809 49-14
E-Mail: christiane.proll(at)

Dr. Reinhard Saller
Tel.:    +49 89 2000 30-30
E-Mail: reinhard.saller(at)

The Ruth Group
Robert Flamm, Ph.D.
Tel.: 1-646-536-7017

Kirsten Thomas
Tel: 1-508-280-6592
E-Mail: kthomas(at)

About numares

numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolics data to develop advanced analytical test tests for high-throughput use in clinical diagnostics and life science research. The AXINON® in-vitro diagnostics (IVD) system employs nuclear magnetic resonance (NMR) spectroscopy to create a “numaric” spectrum to evaluate metabolic constellations. The IVDs based on this metabolic network provide physicians with valuable insights on patient disease status. Magnetic Group Signaling (MGS®) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular diseases, nephrology, oncology and neurology. You will find more information at

You did not activate the necessary cookies for this content.

activate necessary cookies and show content